Literature DB >> 21835801

Timing of the components of the HIV life cycle in productively infected CD4+ T cells in a population of HIV-infected individuals.

John M Murray1, Anthony D Kelleher, David A Cooper.   

Abstract

We estimate the time required for HIV to complete separate stages of its infection cycle in productively infected CD4+ T cells in vivo by comparing initial delays after administration of single antiretroviral drugs until HIV RNA reduction in peripheral blood. Data were obtained from monotherapy studies of eight antiretroviral drugs from all currently licensed HIV drug classes: CCR5 blockers (maraviroc), fusion inhibitors (enfuvirtide), nucleoside and nonnucleoside reverse transcriptase inhibitors (abacavir, tenofovir, and rilpivirine), integrase inhibitors (raltegravir), and protease inhibitors (ritonavir and nelfinavir). We find that HIV requires an average of 52 h between export of virions in one generation to export in the next, with most of this (33 h) taken up by reverse transcription. Reverse transcription in vivo was three times longer than in vitro and began soon after virion fusion, as we determined no difference in mean times for commencement of reverse transcription and virion fusion as calculated by timing of the effects for tenofovir and maraviroc. Approximately 7 h is required between HIV integration and virion production. First-phase HIV RNA decay (half-life of 17 h over all drugs) seemed to slow as the stage being inhibited by the drug was further from viral production. The mean estimated half-life of plasma virions was 5 min, significantly shorter than previous estimates.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21835801      PMCID: PMC3187481          DOI: 10.1128/JVI.05095-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.

Authors:  Jay A Grobler; Geetha Dornadula; Michele R Rice; Amy L Simcoe; Daria J Hazuda; Michael D Miller
Journal:  J Biol Chem       Date:  2006-12-15       Impact factor: 5.157

2.  Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture.

Authors:  Daniel A Donahue; Richard D Sloan; Björn D Kuhl; Tamara Bar-Magen; Susan M Schader; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

3.  Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis.

Authors:  B Ramratnam; S Bonhoeffer; J Binley; A Hurley; L Zhang; J E Mittler; M Markowitz; J P Moore; A S Perelson; D D Ho
Journal:  Lancet       Date:  1999-11-20       Impact factor: 79.321

4.  Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells.

Authors:  Z Zhang; T Schuler; M Zupancic; S Wietgrefe; K A Staskus; K A Reimann; T A Reinhart; M Rogan; W Cavert; C J Miller; R S Veazey; D Notermans; S Little; S A Danner; D D Richman; D Havlir; J Wong; H L Jordan; T W Schacker; P Racz; K Tenner-Racz; N L Letvin; S Wolinsky; A T Haase
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

5.  Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.

Authors:  Daniel R Kuritzkes; Heather J Ribaudo; Kathleen E Squires; Susan L Koletar; Jorge Santana; Sharon A Riddler; Richard Reichman; Cecilia Shikuma; William A Meyer; Karin L Klingman; Roy M Gulick
Journal:  J Infect Dis       Date:  2007-03-06       Impact factor: 5.226

6.  Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients.

Authors:  Miguel Goicoechea; Sonia Jain; Lucun Bi; Carol Kemper; Eric S Daar; Catherine Diamond; Belinda Ha; John Flaherty; Shelly Sun; Douglas Richman; Stan Louie; Richard Haubrich
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

7.  Retroviral intasome assembly and inhibition of DNA strand transfer.

Authors:  Stephen Hare; Saumya Shree Gupta; Eugene Valkov; Alan Engelman; Peter Cherepanov
Journal:  Nature       Date:  2010-01-31       Impact factor: 49.962

8.  Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.

Authors:  John M Murray; Sean Emery; Anthony D Kelleher; Matthew Law; Joshua Chen; Daria J Hazuda; Bach-Yen T Nguyen; Hedy Teppler; David A Cooper
Journal:  AIDS       Date:  2007-11-12       Impact factor: 4.177

9.  Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle.

Authors:  Ahmad R Sedaghat; Jason B Dinoso; Lin Shen; Claus O Wilke; Robert F Siliciano
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

Review 10.  New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.

Authors:  Amelia Hughes; Tristan Barber; Mark Nelson
Journal:  J Infect       Date:  2008-06-16       Impact factor: 6.072

View more
  27 in total

1.  Reply: To PMID 25098971.

Authors:  Jeremie Guedj; Laetitia Canini; Scott Cotler; Harel Dahari
Journal:  Hepatology       Date:  2015-04-18       Impact factor: 17.425

2.  The dynamics of HIV-1 adaptation in early infection.

Authors:  Jack da Silva
Journal:  Genetics       Date:  2011-12-29       Impact factor: 4.562

3.  Within-Epitope Interactions Can Bias CTL Escape Estimation in Early HIV Infection.

Authors:  Victor Garcia; Marcus W Feldman
Journal:  Front Immunol       Date:  2017-05-01       Impact factor: 7.561

Review 4.  Molecular determinants of the ratio of inert to infectious virus particles.

Authors:  P J Klasse
Journal:  Prog Mol Biol Transl Sci       Date:  2014-12-01       Impact factor: 3.622

5.  BCL6 Inhibitor-Mediated Downregulation of Phosphorylated SAMHD1 and T Cell Activation Are Associated with Decreased HIV Infection and Reactivation.

Authors:  Yanhui Cai; Mohamed Abdel-Mohsen; Costin Tomescu; Fengtian Xue; Guoxin Wu; Bonnie J Howell; Yong Ai; Jie Sun; Livio Azzoni; Carole Le Coz; Neil Romberg; Luis J Montaner
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

6.  Kinetics of lentiviral vector transduction in human CD34(+) cells.

Authors:  Naoya Uchida; Rashidah Green; Josiah Ballantine; Luke P Skala; Matthew M Hsieh; John F Tisdale
Journal:  Exp Hematol       Date:  2015-10-21       Impact factor: 3.084

7.  Anti-HIV B Cell lines as candidate vaccine biosensors.

Authors:  Takayuki Ota; Colleen Doyle-Cooper; Anthony B Cooper; Michael Huber; Emilia Falkowska; Katherine J Doores; Lars Hangartner; Khoa Le; Devin Sok; Joseph Jardine; Jeffrey Lifson; Xueling Wu; John R Mascola; Pascal Poignard; James M Binley; Bimal K Chakrabarti; William R Schief; Richard T Wyatt; Dennis R Burton; David Nemazee
Journal:  J Immunol       Date:  2012-10-12       Impact factor: 5.422

8.  Human T helper cells specific for HIV reverse transcriptase: possible role in intrastructural help for HIV envelope-specific antibodies.

Authors:  F Manca; D Fenoglio; M T Valle; G Li Pira; A Kunkl; R S Balderas; R G Baccala; D H Kono; A Ferraris; D Saverino
Journal:  Eur J Immunol       Date:  1995-05       Impact factor: 5.532

9.  Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b).

Authors:  Adriana Andrade; Jeremie Guedj; Susan L Rosenkranz; Darlene Lu; John Mellors; Daniel R Kuritzkes; Alan S Perelson; Ruy M Ribeiro
Journal:  AIDS       Date:  2015-11-28       Impact factor: 4.177

10.  LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions.

Authors:  Belete Ayele Desimmie; Rik Schrijvers; Jonas Demeulemeester; Doortje Borrenberghs; Caroline Weydert; Wannes Thys; Sofie Vets; Barbara Van Remoortel; Johan Hofkens; Jan De Rijck; Jelle Hendrix; Norbert Bannert; Rik Gijsbers; Frauke Christ; Zeger Debyser
Journal:  Retrovirology       Date:  2013-05-30       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.